JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 48:566-575, doi:10.1016/j.jacc.2006.05.044 (Published online 14 June 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Online Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (27)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stone, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stone, P. H.

Antianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine

The ERICA (Efficacy of Ranolazine in Chronic Angina) Trial

Peter H. Stone, MD, FACC*,*, Nikolay A. Gratsiansky, MD{dagger}, Alexey Blokhin, MD{ddagger}, I-Zu Huang, MD§, Lixin Meng, MS, MPH§ for the ERICA Investigators

* Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts
{dagger} Center for Atherosclerosis, Institute of Physicochemical Medicine, Moscow, Russia
{ddagger} Outpatient Clinic of Medical Center of Russian Federation President’s Management Department, Moscow, Russia
§ CV Therapeutics, Palo Alto, California


Figure 1
View larger version (19K):

[in a new window]
  		Figure 1 Study design. BID = twice a day; QD = once per day; RAN = ranolazine.

 

Figure 2
View larger version (32K):

[in a new window]
  		Figure 2 Patient disposition throughout the trial.

 

Figure 3
View larger version (38K):

[in a new window]
  		Figure 3 Number of weekly angina attacks (A) and number of weekly nitroglycerin uses (B), excluding patients with weekly angina rate in the top 2% and bottom 2% of each treatment group (trimmed mean). SE = standard error of the trimmed mean.

 

Figure 4
View larger version (43K):

[in a new window]
  		Figure 4 Number of weekly angina attacks (A) and change from baseline in Seattle Angina Questionnaire (SAQ) angina frequency domain scores (B) for patients with baseline median angina attack rates of ≤4.5 and >4.5 per week within each treatment group (trimmed mean).

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.